Department of Dermatology, Yildirim Beyazit University, Medical School, Ankara, Turkey.
Dermatol Ther. 2019 May;32(3):e12854. doi: 10.1111/dth.12854. Epub 2019 Mar 4.
Intravenous immunoglobulins (IVIG) are therapeutic products, comprising polyclonal IgGs, which are obtained from human plasma pool of healthy blood donors. Despite the lack of Food and Drug Administration (FDA) approval, the experience of using IVIG in various dermatological diseases increases day by day and exciting results are reported. However, experience with the use of IVIG in dermatological indications are mostly case reports whereas randomized, controlled, double-blind, multicentric studies have not been performed. Dermatological diseases treated with IVIG are autoimmune bullous skin diseases, Stevens-Johnson syndrome and toxic epidermal necrolysis, connective tissue diseases, pyoderma gangrenosum, severe atopic dermatitis, chronic urticaria, Kawasaki disease, pretibial myxoedema, scleredema, and graft-versus-host disease.
静脉注射免疫球蛋白（IVIG）是一种治疗产品，包含从健康献血者的人血浆池中获得的多克隆 IgG。尽管缺乏食品和药物管理局（FDA）的批准，但在各种皮肤病中的 IVIG 应用经验日益增加，并且报告了令人兴奋的结果。然而，在皮肤科适应证中使用 IVIG 的经验大多是病例报告，而未进行随机、对照、双盲、多中心研究。用 IVIG 治疗的皮肤病包括自身免疫性大疱性皮肤病、史蒂文斯-约翰逊综合征和中毒性表皮坏死松解症、结缔组织疾病、坏疽性脓皮病、严重特应性皮炎、慢性荨麻疹、川崎病、胫前黏液水肿、硬皮病和移植物抗宿主病。
